- Home
- FLG vs GH Comparison
FLG vs GH Comparison
Compare FLG & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLG
- GH
- Stock Information
- Founded
- FLG 1859
- GH 2011
- Country
- FLG United States
- GH United States
- Employees
- FLG N/A
- GH N/A
- Industry
- FLG
- GH Medical Specialities
- Sector
- FLG
- GH Health Care
- Exchange
- FLG NYSE
- GH Nasdaq
- Market Cap
- FLG 4.9B
- GH 4.7B
- IPO Year
- FLG 1993
- GH 2018
- Fundamental
- Price
- FLG $9.43
- GH $36.66
- Analyst Decision
- FLG Hold
- GH Strong Buy
- Analyst Count
- FLG 4
- GH 14
- Target Price
- FLG $11.88
- GH $39.93
- AVG Volume (30 Days)
- FLG 6.4M
- GH 1.9M
- Earning Date
- FLG 02-15-2025
- GH 02-20-2025
- Dividend Yield
- FLG 0.42%
- GH N/A
- EPS Growth
- FLG N/A
- GH N/A
- EPS
- FLG N/A
- GH N/A
- Revenue
- FLG $1,427,000,000.00
- GH $692,256,000.00
- Revenue This Year
- FLG N/A
- GH $32.21
- Revenue Next Year
- FLG N/A
- GH $16.90
- P/E Ratio
- FLG N/A
- GH N/A
- Revenue Growth
- FLG N/A
- GH 29.20
- 52 Week Low
- FLG $5.10
- GH $15.81
- 52 Week High
- FLG $31.56
- GH $39.29
- Technical
- Relative Strength Index (RSI)
- FLG N/A
- GH 61.33
- Support Level
- FLG N/A
- GH $34.80
- Resistance Level
- FLG N/A
- GH $39.29
- Average True Range (ATR)
- FLG 0.00
- GH 1.92
- MACD
- FLG 0.00
- GH 0.30
- Stochastic Oscillator
- FLG 0.00
- GH 71.96
About FLG FLAGSTAR FINANCIAL INC
Flagstar Financial Inc operates over 400 branches, including a presence in the Northeast and Midwest and locations in high-growth markets in the Southeast and West Coast. In addition, the Bank has approximately 90 private banking teams located in over 10 cities in the metropolitan New York City region and on the West Coast, which serve the needs of high net-worth individuals and their businesses.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.